We have initiated a clinical trial to assess the efficacy and safety of a drug that inhibits the proteases of a bacterium (P.gingivalis) that is detected in the brains of Alzheimer’s patients. It is a new approach to this pathology, absolutely different from the rest of ongoing projects. More information at www.gaintrial.com.
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
Dr Ernest Balaguer highlights the relevance of new therapeutic strategies in Alzheimer’s disease research, including…
The Clarity AD clinical trial has shown relevant results in the study of Alzheimer’s disease,…
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
We have reached the first position, in December 2019, in the international inclusion of patients…
Grifols has reported to the press the positive result of the AMBAR trial in patients…
On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial…
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
Más idiomas
ES / EN / CAT son las versiones oficiales revisadas.
